|Table of Contents|

Short-term efficacy of interventional therapy combined with Lenvatinib and Sintlimab in the treatment of advanced hepatocellular carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 20
Page:
3812-3817
Research Field:
Publishing date:

Info

Title:
Short-term efficacy of interventional therapy combined with Lenvatinib and Sintlimab in the treatment of advanced hepatocellular carcinoma
Author(s):
LIANG Xiong; WU Churong; TANG Wubing; TONG Lihua; CHEN Qisheng; TAN Minghui; LIU Weijian
First Department of General Surgery,the Sixth Affiliated Hospital of South China University of Technology,Guangdong Foshan 528200,China.
Keywords:
advanced liver cancer; interventional therapy; drug therapy; Lenvatinib; Sintlimab
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2023.20.017
Abstract:
Objective:To compared the short-term efficacy and adverse reactions of HAIC combined with Sintlimab and Lenvatinib with that of TACE combined with Sintlimab and Lenvatinib.Methods:Eighty patients who had been confirmed histopathologically or clinically diagnosed as hepatocellular carcinoma were enrolled,and divided into two groups by random number table method.The control group (n=40) was treated with TACE combined with Sintlimab and Lenvatinib,and the observation group (n=40) was treated with HAIC combined with Sintlimab and Lenvatinib.Results:Efficacy in all cases were evaluated one month after the treatments.In observation group,there were 0 case with complete response (CR),20 cases partial response (PR),18 cases with stable disease (SD),and 2 cases with progressive diseas (PD),and the total response rate (CR+PR) was 50.0%.In control group,there were 0 case with CR,14 case with PR,20 cases with SD,and 6 cases with PD.The total effective rate was 35.0%,which was significantly different from that of observation group (P＜0.05).Two groups of ALT,AST,TBil level significantly decreased,observation group significantly lower than the control group (P＜0.05).Two groups significantly lower level of AFP,CEA,AFU,observation group significantly lower than the control group (P＜0.05).Observation group compared with control group adverse reaction no statistical difference (P＞0.05).Conclusion:HAIC combined with Sintlimab and Lenvatinib showed better efficacy than TACE combined with Sintlimab and Lenvatinib,and had lower adverse reactions.

References:

［1］ SUNG H,FERLAY J,SIEGELl RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］ HATANAKA T,NAGANUMA A,KAKIZAKI S,Lenvatinib for hepatocellular carcinoma：a literature review［J］.Pharmaceuticals(Basel),2021,14(1):36.
［3］ BENSON ALBD,ANGELICA MICHAEL I,ABBOTT DANIEL E.Guidelines insights:hepatobiliary cancers,version 2.2019［J］.J Natl Compr Canc Netw,2019,17:302-310.
［4］ 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版)［J］.中华消化外科杂志,2022,21(2):143-168. Medical Administration Bureau of the National Health Commission of the People's Republic of China.Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition)［J］.Chinese Journal of Digestive Surgery,2022,21(2):143-168.
［5］ ACKSON R,PSARELLI EE,BERHANE S,et al.Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer:a meta-analysis of randomized phase Ⅲ trials［J］.J Clin Oncol,2017,35(6):622-628.
［6］ KUDO M,FINN RS,QIN S,et al.Lenvatinib versus sorafenib in first line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial［J］.Lancet,2018,391(10126):1163-1173.
［7］ NAIR A,REECE K,DOMOGHUE MB,et al.FDA supplemental approval summary:lenvatinib for the treatment of unresectable hepatocellular carcinoma［J］.Oncologist,2020,26(3):e484-e494.
［8］ CHENG H,SUN G,CHEN H,et al.Trends in the treatment of advanced hepatocellular carcinoma:immune checkpoint blockade immunotherapy and related combination therapies［J］.Am J Cancer Res,2019,9(8):1536-1545.
［9］ PINATO DJ,GUERRA N,FESSAS P,et al.Immune-based therapies for hepatocellular carcinoma［J］.Oncogene,2020,39(18):3620-3637.
［10］ FINN RS,QIN S,IKEDA M,et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma［J］.N Engl J Med,2020,382(20):1894-1905.
［11］ FINN RS,IKEDA M,ZHU AX,et al.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma［J］.J Clin Oncol,2020,38(26):2960-2970.
［12］ XU J,SHEN J,GU S,et al.Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE):A Nonrandomized,Open-label,Phase II Trial［J］.Clin Cancer Res,2021,27(4):1003-1011.
［13］ REN Z,XU J,BAI Y,et al.Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32):a randomised,open-label,phase 2-3 study［J］.The Lancet Oncology,2021,22(7):977-990.
［14］ GU YK,ZHANG TQ,HUANG ZL,et al.Hepatic artery infusion chemotherapy combined with apatinib and toripalimab in advanced hepatocellular carcinoma:real-world data from a single center ［J/OL］.Journal of Clinical Oncology,2020,38［2022-06-01］.http://dx.doi.org/10.1200/JCO.2020.38.15_suppl.e16602.DOI:10.1200/JCO.2020.38.15_suppl.e16602.
［15］ HE MK,LIANG RB,ZHAO Y,et al.Lenvatinib,toripalimab,plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma［J］.Therapeutic Advances in Medical Oncology,2021,13:175-272.
［16］ MEI J,TANG YH,WEI W,et al.Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma［J/OL］.Frontiers in Oncology,2021,11［2022-06-01］.https://pubmed.ncbi.nlm.nih.gov/33718175/.DOI:10.3389/fonc.2021.618206.
［17］ CHEN S,XU B,WU Z,et al.Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining:a multicenter retrospective study［J］.BMC Cancer,2021,21(1):1126.
［18］ ZHANG TQ,ZUO MX,GENG ZJ,et al.946P hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage C:a prospective,single-arm,phase II trial (TRIPLET study) ［J］.Annals of Oncology,2021,32:S825.
［19］ GRETEN TF,MAUDA-HAVAKUK M,HEINRICH B,et al.Combined locoregional-immunotherapy for liver cancer［J］.J Hepatol,2019,70(5):999-1007.
［20］ HACK SP,ZHU AX,WANG Y.Augmenting anticancer immunity through combined targeting of Angiogenic and PD-1/PD-L1 pathways:challenges and opportunities［J］.Front Immunol,2020,11:598-877.
［21］ European Association for the Study of the Liver.EASL clinical practice guidelines:management of hepatocellular carcinoma［J］.J Hepatol,2018,69(1):182-236.
［22］ MARTINEZ A,SANTANA N,SANTIAGO S,et al.Using the common terminology criteria for adverse events (CTCAE Version 5.0) to evaluate the severity of adverse events of anticancer therapies［J］.Actas Dermosifililiogr(Enggl Ed),2021,112(1):90-92.
［23］ DIMRI M,SATYANARAYANA A.Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma［J］.Cancers (Basel),2020,12(2):491.
［24］ LLOVET JM,KELLEY RK,VILLANUEVA A,et al.Hepatocellular carcinoma［J］.Nat Rev Dis Primers,2021,7(1):6.
［25］ CASADEI GARDINI A,PUZZONI M,MONTAGNANI F,et al.Profile of lenvatinib in the treatment of hepatocellular carcinoma:design,development,potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials［J］.Onco Targets Ther,2019,12:2981-2988.
［26］ SINGH A,BEECHINOR RJ,HUYNH JC,et al.Immunotherapy updates in advanced hepatocellular carcinoma［J］.Cancers (Basel),2021,13(9):2164.
［27］ XU J,SHEN J,GU S,et al.Camrelizumab in combination with Apatinib in patients with advanced hepatocellular carcinoma (RESCUE):A nonrandomized,open-label,phase II trial［J］.Clin Cancer Res,2021,27(4):1003-1011.
［28］ YAU T,PARK JW,FINN RS,et al.LBA38_PR-check mate 459:A randomized,multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (a HCC)［J］.Annals of Oncology,2019,30:v874-v875.
［29］ LYU N,LIN Y,KONG Y,et al.FOXAI:a phaseⅡtrial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma［J］.Gut,2018,67(2):395-396.
［30］ HE MK,LI QJ,ZOU RH,et al.Sorafenib plus hepatic arterial infusion of oxaliplatin,fluorouracil,and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion:a randomized clinical trial［J］.JAMA Oncology,2019,5(7):953-960.
［31］ SHI M,LI Q,HE M,et al.981O hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin,fluorouracil,and leucovorin (FOLFOX) versus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC):a randomised phase III trial［J］.Annals of Oncology,2020,31:S688.

Memo

Memo:
-
Last Update: 1900-01-01